AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
Express News | Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices
AstraZeneca Hits 4-week Low
Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices
AstraZeneca (AZN) Receives a Hold From Jefferies
Express News | AstraZeneca : Jefferies Raises Target Price to $74 From $71
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
The European Medicines Agency (EMA) has accepted AstraZeneca Plc's (NASDAQ:AZN) marketing authorization application for sipavibart for pre-exposure prophylaxis (prevention) of COVID-19 in immunocompro
AstraZeneca Shares Update and Global Reach
Express News | AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application
AstraZeneca (AZN.L, AZN.ST) said Monday that the European Medicines Agency's Committee for Medicinal products for Human Use recommended for approval its combination formulation of Imfinzi and Lynparza
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU
AstraZeneca (AZN.L, AZN.ST) on Monday said the European Medicines Agency accepted its marketing authorization application for its COVID-19 prevention antibody sipavibart under an accelerated assessmen
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Why Astrazeneca (AZN) Is a Top Growth Stock for the Long-Term
GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca
New York, USA, June 26, 2024 (GLOBE NEWSWIRE) -- GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China.
AstraZeneca's Tagrisso Receives Approval in Japan for Lung Cancer
Express News | China Approves AstraZeneca's Tagrisso (Osimertinib) With The Addition Of Pemetrexed And Platinum-based Chemotherapy For The First-Line Treatment Of Locally Advanced Or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer